NCT02662582View on ClinicalTrials.gov

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 8, 2018

Study Completion Date

June 8, 2018

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Reldesemtiv

Oral tablet

DRUG

Placebo

Oral tablet

Trial Locations (2)

15213

Site US10003, Pittsburgh

90502

Site US10001, Torrance

Sponsors

Collaborators (1)

Cytokinetics
All Listed Sponsors
collaborator

Cytokinetics

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02662582 - A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter